vTv Therapeutics Inc.: directors' dealings · United States · SEC (Form 4)

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker VTVT. Headquartered in High Point, North Carolina, United States, the company is focused on discovering and developing oral, small-molecule drug candidates aimed at chronic diseases with significant unmet medical need. Its business model is that of a clinical-stage developer rather than a commercial pharma company, meaning the investment case is driven primarily by data readouts, regulatory milestones and financing capacity rather than product sales. ([vtvtherapeutics.com](https://vtvtherapeutics.com/about/?utm_source=openai)) The company’s current strategy is centered on cadisegliatin, its lead clinical asset. vTv describes cadisegliatin as a potential first-in-class, oral, liver-selective glucokinase activator being investigated as an adjunct to insulin for type 1 diabetes (T1D). That positioning matters: if successful, an oral add-on therapy could offer a differentiated approach in a market that is still heavily reliant on injectable insulin-based regimens. vTv has also historically referenced a broader research portfolio spanning other chronic-disease targets and partner-led programs, including areas such as type 2 diabetes and inflammatory disorders, although the near-term value driver remains the T1D program. ([vtvtherapeutics.com](https://www.vtvtherapeutics.com/?utm_source=openai)) From a competitive standpoint, vTv Therapeutics sits in the high-risk/high-reward segment of small-cap biotech. The company competes with larger, better-capitalized pharmaceutical players and with other clinical-stage developers pursuing diabetes innovation. Its competitive differentiation comes from the oral small-molecule profile of its lead candidate and the potential to address unmet needs in glycemic control. At the same time, the company does not yet have a broad commercial footprint, so its market position is still defined more by pipeline optionality than by revenue scale or established product franchises. ([vtvtherapeutics.com](https://www.vtvtherapeutics.com/?utm_source=openai)) Recent developments have been important for the investment narrative. In March 2025, vTv reported that the FDA clinical hold on cadisegliatin, imposed in July 2024, had been lifted, which materially improved the program’s trajectory. In February 2025, the company announced an $80 million private placement with healthcare institutional investors and the T1D Fund, strengthening its balance sheet. More recently, vTv issued quarterly updates through late 2025 and filed its Form 10-Q in May 2026, underscoring that execution, cash management and upcoming clinical catalysts remain central to the story. ([stocklight.com](https://stocklight.com/stocks/us/nasdaq-vtvt/vtv-therapeutics/annual-reports/nasdaq-vtvt-2025-10K-25756857.pdf?utm_source=openai))